Navidea Biopharmaceuticals Reports Third Quarter and Year-to-Date 2020 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/12/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Navidea Biopharma (NAVB) Misses Q3 EPS by 4c
November 12, 2020 4:04 PM ESTNavidea Biopharma (NYSE: NAVB) reported Q3 EPS of ($0.13), $0.04 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $268 thousand versus the consensus estimate of $150 thousand.
Third Quarter 2020 Highlights and Subsequent Events
Executed a binding memorandum of understanding (MOU) on August 9, 2020 with Jubilant Draximage Inc. dba Jubilant Radiopharma, Radiopharmaceuticals Division (Jubilant). The MOU outlines the terms and framework for an Exclusive License and Distribution Agreement for Navideas Rheumatoid Arthritis Diagnostic in the United States, Canada, Mexico, and Latin America. In connection with the MOU, Jubilant made a $1 million equity investment in... More